Tg2576 mice overexpress a mutant form of human amyloid precursor protein with the Swedish mutation (APP Sw ), resulting in high ␤-amyloid (A␤) levels in the brain. Despite this, amyloid plaques do not develop until 12 months of age, and there is no neuronal loss in mice as old as 16 months. Gene expression profiles in the hippocampus and cerebellum of 6-month-old APP Sw mice were compared with age-matched controls. The expression of transthyretin, a protein shown to sequester A␤ and prevent amyloid fibril formation in vitro, and several genes in the insulin-signaling pathway, e.g., insulin-like growth factor-2, were increased selectively in the hippocampus of APP Sw mice. Concomitant activation of the insulin-like growth factor-1 receptor, Akt, and extracellular signal-regulated protein kinase 1 and 2 as well as increased phosphorylation of Bad also were unique to the hippocampus of APP Sw mice. In addition, the increased expression of transthyretin and insulin-like growth factor-2 and the increased phosphorylation of Bad in hippocampal neurons were maintained in 12-month-old APP Sw mice when compared with age-matched controls. These results suggest that the slow progression and lack of full-fledged Alzheimer's disease pathology in the hippocampal neurons of APP Sw mice result from the genetic reprogramming of neural cells to cope with increased levels of A␤.
Alzheimer's disease (AD) is the most common cause of senile dementia. AD is associated with ␤-amyloid (A␤) plaques, neurofibrillary tangles, and large-scale neuronal cell loss. Multiple lines of evidence implicate A␤ as the causative agent in AD. For instance, familial AD is linked to mutations in the amyloid precursor protein (APP), presenilin 1, and presenilin 2, all of which lead to increased levels of A␤. In addition, transgenic mice overexpressing the mutant genes linked to familial AD produce high levels of A␤, exhibit some of the pathological features of AD, and demonstrate behavioral and learning deficits later in life (Duff et al., 1996; Hsiao et al., 1996; Holcomb et al., 1998) . Both the density of plaques and the cognitive changes can be reversed by vaccination against A␤ (Janus et al., 2000; Morgan et al., 2000) . Finally, A␤ leads to neuronal death in cell culture and in vivo (Yankner et al., 1990; Giovannelli et al., 1995; Calhoun et al., 1998) . The formation of extracellular plaques is common to all lines of transgenic mice overexpressing high levels of mutant APP. However, in contrast to the human disease, most lack neurofibrillary tangles (NFTs) and demonstrate little or no neuronal cell loss (Duff et al., 1996; Hsiao et al., 1996; Irizarry et al., 1997a,b; Holcomb et al., 1998) . These mice, therefore, may not be a good model of the complete pathologic process of AD but rather may be an excellent model for understanding how the brain can adapt to and survive high levels of A␤.
Tg(HuAPP695.K670N-M671L)2576 mice overexpressing APP with the Swedish mutation (APP Sw ) have markedly increased A␤ levels beginning as early as 2 months of age, and extracellular plaques begin to form in the cortex and hippocampus between 8 and 12 months (Hsiao et al., 1996; Kawarabayashi et al., 2001 ). In addition, 8,12-iso-iPF 2␣ -VI, a marker for lipid peroxidation, is increased beginning at 7-8 months of age (Pratico et al., 2001) , and the levels of oxidized proteins are 12-fold higher compared with nontransgenic animals (Lim et al., 2001) . Despite the well characterized toxicity of A␤ as well as the evidence of increased oxidative stress and other pathologies in APP Sw mice, there is no neuronal cell loss (Irizarry et al., 1997a) . Therefore, we were interested in early gene expression changes that might mediate neuroprotection in these mice. In both humans and APP Sw mice the hippocampus is highly susceptible to A␤ accumulation and plaque development, whereas the cerebellum does not develop significant amyloid deposits (Irizarry et al., 2001; Pratico et al., 2001) . Thus the present study was designed to determine gene expression profiles in the hippocampus and cerebellum of 6-month-old APP Sw mice compared with age-matched controls and to identify potential mechanisms responsible for protecting neurons from A␤ toxicity.
MATERIALS AND METHODS
Animals. Tg2576 mice were created as described previously (Hsiao et al., 1996) . Briefly, they contain the human APP 695 with the double mutation K670N and M671L (Swedish mutation) and are driven by the prion protein promoter. In this study, transgenic and nontransgenic control mice were generated from C57B6/SJL N2 generation Tg2576 mice backcrossed to C57B6/SJL breeders. Mice were killed at 6 and 12 months of age.
Oligonucleotide microarray. Male mice were killed with C O 2 and im-mediately perf used through the heart with PBS. The hippocampus and cerebellum were dissected and stored in liquid nitrogen. Total RNA was extracted with Trizol (Invitrogen, C arlsbad, CA) after tissue homogenization. Double-stranded cDNA was synthesized from the total RNA by using a Superscript choice kit (Invitrogen) with a T7-dT 24 primer incorporating a T7 RNA polymerase promoter. The cRNA was prepared and biotin-labeled by in vitro transcription (Enzo Biochem, New York, N Y). Labeled cRNA was fragmented by incubation at 94°C for 35 min in the presence of 40 mM Tris-acetate, pH 8.1, 100 mM potassium acetate, and 30 mM magnesium acetate. Then 15 g of fragmented cRNA was hybridized for 16 hr at 45°C to a MG-74Av2 array (Aff ymetrix, Santa C lara, CA). After hybridization the gene chips were washed automatically and stained with streptavidin -phycoerythrin by using a fluidics station. Finally, probe arrays were scanned at 3 m resolution by using the Genechip System confocal scanner made for Aff ymetrix by Aligent. Aff ymetrix Microarray Suite 4.1 was used to scan and analyze the relative abundance of each gene from the average difference of intensities (Lipshutz et al., 1999) . Analysis parameters used by the software were set to values corresponding to moderate stringency (SDT ϭ 30; SRT ϭ 1.5).
We scaled the data from each array to normalize for comparisons.
Output from the microarray analysis was merged with the Unigene or GenBank descriptor. Each sample was run on a single array, and the comparisons were crossed such that each APP Sw transgenic animal was compared with each control for a total of nine comparisons (3 ϫ 3 matrix). The average difference change (ADC) is defined as the difference between the relative level of transcript expression in APP Sw mice versus nontransgenic control mice. The definition of increase, decrease, or no change of expression for individual genes was based on ranking the Difference C all (as determined by the Aff ymetrix software) from three intergroup comparisons (3 ϫ 3), namely, No Change ϭ 0, Marginal Increase/ Decrease ϭ 1/Ϫ1, Increase/ Decrease ϭ 2/Ϫ2. The final rank was calculated by summing up the individual ranks from each comparison, and the value varied from Ϫ18 to 18. The cutoff value for the final determination of Increase/ Decrease was set as 9/Ϫ9. Genes for which the coefficient of variance was Ͼ1.0 were not included in the final list, and changes of Ͻ1.5-fold also were eliminated. Using this kind of data analysis with three replicates generated a conservative list of genes with changed expression levels. RT-PCR of selected genes confirmed the microarray results. Gene classification was based on a literature review.
Reverse transcription-PCR . RNA was isolated from the hippocampus of 6-and 12-month-old mice with Trizol (Invitrogen). RNA (1 g) was reverse transcribed for 1 hr at 42°C by using an oligo-dT 15 primer from the Reverse Transcription System (Promega, Madison, W I). The resulting cDNA was amplified by PCR that used primer sets designed with PRIM ER3 (available at w w w.genome.wi.mit.edu /cgi-bin /primer/ primer3_w w w.cgi) and that used sequence data from the National C enter for Biotechnology Information (Bethesda, MD) database. Primers (purchased from I DT, Coralville, IA) were designed for APP Sw (5Ј primer, AC TGGC TGAAGAAAGTGACAAT and 3Ј primer, AGAGGTGGTTCGAGTTCC TACA), resulting in a PCR product of 310 base pairs (bp); transthyretin (5Ј, CCATAC TCC TACAGCACCAC and 3Ј, GCATC TACAGCCC TTCAG), resulting in a PCR product of 488 bp; insulin-like growth factor-2 (5Ј, AACCCGAGAAGAAAG-GAAG and 3Ј, TCACACATAGAGCCAATAAGC), resulting in a PCR product of 550 bp; and ␤-actin (5Ј, CCCAGAGCAAGAGAGGTATC and 3Ј, AGAGCATAGCCCTCGTAGAT), resulting in a PCR product of 340 bp.
Immunohistochemistr y. Mice were killed with C O 2 and immediately perf used through the heart with PBS. The right hemispheres were fixed in 4% paraformaldehyde overnight, sunk in 30% sucrose, and frozen in OC T embedding medium. Frozen sections with a width of 10 m were taken through the hippocampus and cerebellum. Insulin-like growth factor-2 (IGF-2) was detected with a 1:200 dilution of the polyclonal antibody against IGF-2 (F-20; Santa Cruz Biotechnology, Santa Cruz, CA). Phospho-Akt (Thr308), Akt, phospho-Erk1/2 (Thr202/ T yr204), Erk1/2, phospho-Bad (Ser112), and Bad were detected with a 1:100 (phospho-Akt, Akt, phospho-Erk1/2, and Erk1/2) or 1:1000 (phosphoBad and Bad) dilution of the respective polyclonal antibody (C ell Signaling, Beverly, M A). As a control, preimmune rabbit IgG (Vector Laboratories, Burlingame, CA) was used in place of the primary antibody. The Vectastain Elite ABC kit and 3, 3Ј-diaminobenzidine were used to visualize the antibody staining, and selected sections with each antibody were counterstained with hematoxylin (Vector Laboratories). The figures are representative of the results obtained from three APP Sw mice and three nontransgenic controls.
Immunoprecipitation and Western immunoblot. Protein was isolated with Trizol (Invitrogen) from the dissected hippocampus and cerebellum of three APP Sw mice and three nontransgenic controls. Immunoprecipitation was performed on 500 g of protein by using a 1:100 dilution of the phosphotyrosine monoclonal antibody P-T yr-100 (C ell Signaling). The precipitated protein then was run on a gel and immunoblotted with a 1:200 dilution of 24-31, a monoclonal antibody against IGF-1R␤ (Chemicon, Temecula, CA). Additional Western immunoblots were performed on 60 g of protein by using polyclonal antibodies against Bad and phospho-Bad (Ser112; C ell Signaling). Bands were visualized by using horseradish peroxidase-conjugated secondary antibodies and SuperSignal West Pico chemiluminescent substrate (Pierce, Rockford, IL).
RESULTS Microarray
Initially, we determined the gene expression profiles of the hippocampus and cerebellum from 6-month-old APP Sw mice (n ϭ 3) compared with nontransgenic littermates (n ϭ 3), using oligonucleotide arrays containing 12,427 mouse genes and expressed sequence tags (ESTs). Decreased genes and ESTs totaled 41 in the hippocampus (Table 1 ) and two in the cerebellum (Table 2 ). In the hippocampus 24 transcripts were increased in Tg2576 mice, four of which were ESTs (Table 1) . Two of these genes, transthyretin and ectonucleotide pyrophosphatase/phosphodiesterase 2, also were increased in the cerebellum, where a total of seven genes had increased expression. However, the magnitude of the increase was reduced greatly in the cerebellum (see Table 2 ).
Increased expression of transthyretin
The most dramatic change in gene expression was for the transcript encoding for transthyretin (TTR), a thyroid hormone binding protein abundant in serum (see Table 1 ). Transthyretin is the major A␤ binding protein in the CSF and inhibits A␤ aggregation and fibril formation in vitro (Schwarzman et al., 1994) . In the APP Sw mice TTR mRNA was increased 29.5-fold in the hippocampus and 3.2-fold in the cerebellum. Immunohistochemistry also revealed markedly increased levels of TTR protein throughout the hippocampus with concentrations around the neurons of CA1-CA3 and the dentate gyrus (DG) (Fig. 1 ).
Increased expression of genes involved in growth factor pathways
Six genes with increased expression are growth factors or related to growth factor pathways. These include insulin-like growth factor-2 (IGF-2), insulin-like growth factor binding protein 2 (IGFBP-2), adenylate cyclase-activating polypeptide 1, growth hormone receptor, and prolactin receptor (see Table 1 ). Because IGF-2 expression was increased dramatically in the hippocampus of APP Sw mice (see Table 1 ) and IGF-2 protein has been shown to protect cultured neurons from A␤ toxicity , we examined cell survival pathways that may be activated by IGF-2. Immunohistochemistry revealed a substantial increase of IGF-2 in the hippocampus (Fig. 2 A-F ), but not in the cerebellum (Fig.  2G ,H ), of APP Sw overexpressing mice. A high level of IGF-2 was found throughout the hippocampus but mostly was localized around the pyramidal neurons within CA1-CA3 and the granule cells of the DG (Fig. 2 B 
,D,F ).

Activated pathways downstream of IGF-2
The ␤-subunit of the IGF-1 receptor (IGF-1R␤) is tyrosine phosphorylated with the binding of IGF-1, IGF-2, or insulin. Consistent with the increase of IGF-2 in APP Sw mice, the level of tyrosine-phosphorylated IGF-1R␤ is increased in the hippocampus when compared with control animals (Fig. 3A) . Phosphatidyl inositol 3-kinase (PI3-K) is activated by receptor tyrosine kinases such as IGF-1R␤ and subsequently can activate the serine/threonine kinase Akt. Akt protects cells from a variety of death-promoting insults, including A␤ toxicity (Martin et al., 2001) . Akt is activated by phosphorylation at threonine 308, and the neuronal fields in CA1-CA3 and in the DG expressed low levels of Thr308 phospho-Akt in control animals ( Fig. 3B,E ). In contrast, the level of phospho-Akt was increased markedly in these neurons in mice overexpressing APP Sw (Fig. 3C,F ) . When activated, Akt translocates to the nucleus (Kawano et al., 2001) , and, in fact, much of the phospho-Akt was within the nucleus of hippocampal neurons in APP Sw mice (Fig. 3D,G) . Furthermore, Akt phosphorylates and inhibits glycogen synthase kinase-3 (GSK-3), an enzyme thought to contribute to tau hyperphosphorylation in AD, suggesting that, in APP Sw mice, tau phosphorylation may be inhibited through this pathway. Tyrosine receptor kinases, e.g., IGF-1, growth hormone (GH), and prolactin receptors, can activate mitogen-activated protein kinase (MAPK) by sequential activation of Ras, Raf, MEK, and the MAPK extracellular signal-regulated protein kinase 1 and 2 (Erk1/2). Akt also can activate Ras, leading to increased Erk1/2 activity. Erk1 activity is dependent on phosphorylation at threonine 202 and tyrosine 204, whereas Erk2 activity is induced by phosphorylation at threonine 183 and tyrosine 185. A previous report demonstrated by immunoblotting that APP Sw mice have increased phospho-Erk1/2 in the DG at 4 and 13 months of age (Dineley et al., 2001) . Consistent with this and with activation of IGF-1R (Fig. 3A) , we show increased immunostaining for phospho-Erk1/2 in the neurons in CA1 and DG of 6-month-old APP Sw mice (Fig. 3H-M ) . Similar to phospho-Akt, phosphoErk1/2 is found predominantly in the nucleus of these neurons (Fig. 3J,M ) while being virtually undetectable in the hippocampus of control mice.
Interestingly, both activated Akt and Erk1/2 can lead to the phosphorylation of the proapoptotic protein Bad (Datta et al., 1997; Bonni et al., 1999) . When phosphorylated at serine 112 or 136, Bad binds to 14-3-3 proteins and releases the anti-apoptotic Bcl-2 family members, Bcl-xl and Bcl-2. Immunohistochemistry for phospho-Bad shows a dramatic increase in the neurons of CA1 and DG in 6-month-old APP Sw mice compared with nontransgenic controls (Fig. 4) . Similar to the immunostaining for IGF-2 and immunoprecipitation for activated IGF-1R␤, immunohistochemistry in the cerebellum for phospho-Akt, phosphoErk1/2, and phospho-Bad also showed no difference between nontransgenic and APP Sw mice (data not shown).
The microarray analysis indicated no change in the expression of Bad (rank ϭ 0), Akt1 (rank ϭ Ϫ2), Akt2 (rank ϭ 2), Erk1 (rank ϭ 0), and Erk2 (rank ϭ 0) (data not shown). Immunohistochemistry in the hippocampus for Akt1, Akt2, and Akt3 dem- onstrated similar levels in both nontransgenic and APP Sw mice. Antibodies directed against total Bad and Erk1/2 did not stain hippocampal neurons with any greater intensity than preimmune rabbit IgG, implying that, under the conditions described here, these antibodies were unable to recognize their antigen. Alternatively, Western immunoblot for total Bad and Erk1/2 demonstrated specific bands in hippocampal extracts that were unchanged in intensity between nontransgenic and APP Sw mice (data not shown).
Changes in TTR, IGF-2, and phospho-Bad before and after plaque deposition
Levels of TTR and IGF-2 mRNA are increased in the hippocampus of mice that express the human APP Sw transcript (Fig. 5) . In agreement with our microarray data, RT-PCR reveals a slight increase of TTR mRNA levels in the cerebellum of two of three APP Sw mice. There is no consistent change in IGF-2 levels in the cerebellum, however (Fig. 5A ). In the hippocampus both TTR and IGF-2 have increased expression at 6 months of age (preplaque) (Fig. 5A ) and 12 months of age (postplaque) (Fig. 5B) . Consistent with the increase in IGF-2 and with the activation of downstream kinase pathways in 6-month-old APP Sw mice, 12-month-old APP Sw mice also have increased levels of phospho-Bad in the neurons of CA1 and the DG when compared with nontransgenic littermates (Fig. 6) .
DISCUSSION
We have shown that the expression of a number of protective genes and a protective pathway culminating in Bad phosphorylation are increased in mice that overexpress APP Sw and have no neuronal loss. Increased levels of IGF-2 mRNA and protein correspond to increased activation of the IGF-1 receptor, activation of Akt and Erk1/2, and phosphorylation of Bad in APP Sw mice. The increased expression of TTR and IGF-2 as well as increased phospho-Bad staining in hippocampal neurons was consistent in both preplaque (6 months) and postplaque (12 months) Tg2576 mice. Other conditions, such as the presence of a human tau gene, may be necessary for complete AD pathology. However, taken together, these data imply that the lack of neurodegeneration in APP Sw mice is a result of the activation of known cell survival pathways associated with the overexpression of APP Sw .
Transthyretin has been shown to bind A␤ and inhibit A␤ Figure 5 . RT-PCR from the hippocampus and cerebellum of APP Sw and nontransgenic mice. A, The 6-month-old mice that contain and express the human APP Sw transgene (lanes 2, 4, 6 ) have increased levels of transthyretin (TTR) and insulin-like growth factor-2 (IGF-2) in the hippocampus when compared with nontransgenic littermates (lanes 1, 3, 5 ). In the cerebellum the increase in TTR expression is reduced and the increase in IGF-2 is eliminated when comparing APP Sw mice (lanes 2, 4, 6 ) with nontransgenic littermates (lanes 1, 3, 5) . B, At 12 months the increased expression of TTR and IGF-2 in the hippocampus of APP Sw mice remains (lanes 2, 4 ) when compared with nontransgenic controls (lanes 1, 3) . aggregation (Schwarzman et al., 1994) . In human AD patients the concentration of TTR is significantly lower than in age-matched controls (Serot et al., 1997) . This, in part, may contribute to the increased levels of A␤ in AD brains. In contrast, one reason why significant plaque deposition does not occur until 12 months of age in the mice overexpressing APP Sw may be the dramatic increase of TTR. Several growth factors and growth factor pathways that can culminate in cell survival and the activation of Akt or Erk1/2 kinase pathways are upregulated in APP Sw mice. For example, pituitary adenylate cyclase-activating polypeptide (PACAP) has been shown to stimulate neurite outgrowth, regulate neurotransmitter production, and promote neuronal survival via the inhibition of caspase-3 activity (Vaudry et al., 2000) . Growth hormone receptor is expressed on multiple cell types throughout the brain, and intraventricular injection of GH has reduced neuronal loss in the frontoparietal cortex and hippocampus after an ischemic brain injury (Scheepens et al., 2001) . In cell lines, GH has inhibited apoptosis induced by the withdrawal of survival factors via the activation of the receptor-associated tyrosine kinase Janus kinase 2 (JAK2), PI3-K, and the serine-threonine kinase Akt (Costoya et al., 1999) . Similarly, prolactin acts via its receptor to activate JAK2 and PI3-K (Berlanga et al., 1997) . IGF-2 has been shown to protect against A␤ toxicity in culture, and its protective action is thought to be mediated via the activation of the IGF-1 receptor and subsequent activation of Akt and MAPK (Webster et al., 1994; Dore et al., 1997; Zheng et al., 2000) . IGF-2 receptors also are abundant on the hippocampal neurons of CA1-CA3 and the DG and may be important in regulating acetylcholine release in these regions . In addition, IGF-2 and IGFBP-2 are expressed coordinately in many tissues (Logan et al., 1994) and in response to brain injury (Beilharz et al., 1998) . IGFBP-2 has been suggested to prolong the biological activity and to be a key transport protein for IGF-2. Our data indicate that the principal components of multiple signal transduction cascades known to promote cell survival are increased selectively in the hippocampus of APP Sw mice, suggesting that the cell death signals associated with A␤-induced neurodegeneration can be balanced successfully by increasing those that are advancing cell life.
Interestingly, some of the decreased genes have been well characterized and appear to contribute to apoptosis. For example, protein tyrosine phosphatase, nonreceptor-type substrate 1 (SHPS-1), is decreased by 2.9-fold in the hippocampus and has been shown to regulate growth factor pathways negatively. In glioblastoma cells the human homolog of SHPS-1, SIRP␣, inhibits epidermal growth factor-induced activation of PI3-K and leads to reduced transformation and migration and enhanced apoptosis (Wu et al., 2000) . Two other decreased genes, c-fos and mitogenactivated protein kinase kinase kinase 4 (MEKK4b), also are involved in apoptosis. In addition to playing a role in cell growth and development, c-fos has been shown to mediate apoptosis in response to growth factor deprivation and cell injury (Estus et al., 1994; Preston et al., 1996; Hafezi et al., 1997) . In AD c-Fos and c-Jun are increased within neurons of the hippocampus where significant apoptosis occurs, but not in the cerebellum where there is no increase in apoptotic cells (Marcus et al., 1998) . In a separate pathway, MEKK4b activates the c-Jun NH 2 -terminal kinase cascade that is thought to contribute to apoptosis and neurodegeneration (Gerwins et al., 1997) . Thus in combination with the increased genes and survival pathways discussed above, the decreased expression of these genes also may help to prevent the activation of apoptotic pathways by A␤ in the APP Sw mice.
Two recent publications have suggested an association between folate and AD. An increased level of homocysteine, which can result from folate deficiency, is a strong risk factor for the development of Alzheimer's disease (Seshadri et al., 2002) . In addition, a folate-deficient diet in a transgenic mouse model overexpressing APP Sw results in neurodegeneration in the CA3 region of the hippocampus, and in hippocampal cultures homocysteine augmented A␤-induced neuronal death (Kruman et al., 2002) . Folate binding protein 1 is increased in the hippocampus of APP Sw mice (see Table 1 ) and acts as a receptor to mediate the delivery of 5-methyltetrahydrofolate to the interior of cells. Based on the findings discussed above, the almost fourfold increase in folate binding protein may prevent the accumulation of homocysteine in the hippocampus and help to prevent A␤-induced neurodegeneration.
In addition to the potentially protective gene expression changes discussed above, the aging gene, klotho, was increased more than sixfold in the hippocampus of APP Sw mice (see Table  1 ). Mice containing a knock-out of the gene klotho develop several age-related disorders and die prematurely. Abnormalities in the mutant klotho mice include growth retardation, arteriosclerosis, and atrophy of the growth hormone-producing cells in the pituitary gland (Kuro-o et al., 1997) . Many of these disorders may contribute to and/or be augmented by A␤-induced pathology. Systemic administration of the klotho gene reversed the pathology in the mutant klotho mice (Shiraki-Iida et al., 2000) . Thus, in APP Sw mice increased klotho may help to protect against high A␤ levels.
Despite the lack of NFTs and neuron loss, A␤ levels are high in APP Sw mice, and some cognitive deficits have been documented. Behavioral testing reveals spatial learning and memory deficits beginning at 9 months of age (Hsiao et al., 1996) . Our microarray analysis shows expression changes in some genes that may mediate part of this cognitive decline. Specifically, chloride channel protein 3 (CLCN3) was decreased in the hippocampus of APP Sw mice (see Table 1 ). CLCN3 is expressed on the synaptic vesicles of hippocampal neurons, and its disruption in mice results in severe degeneration of the hippocampus and consequent memory impairments (Stobrawa et al., 2001) . Numerous other genes encoding for proteins involved in the cell cycle, transcription regulation, DNA replication, tissue remodeling, and cell-to-cell communication were changed selectively in the hippocampus of APP Sw mice (see Table 1 ). The contribution of these genes to the limited pathology or to the delayed plaque deposition and lack of neuronal loss in the APP Sw mice requires further investigation.
Many of the neuroprotective genes and signaling pathways described here have not been characterized fully in the human disease, and it is not clear what role they have in AD. We speculate that the surviving neurons without tau pathology (phospho-tau-negative neurons) would have neuroprotective gene expression changes, Akt and Erk1/2 activation, and Bad phosphorylation. In contrast, dying neurons (phospho-taupositive neurons) would not show these changes because of an apoptosis-induced shutdown of these protective pathways. In support of this hypothesis, a recent publication found that phospho-Erk1/2 is increased in a subpopulation of neurons with little or no phospho-tau staining, whereas Erk1/2 was unchanged in neurons with dense NFTs or DNA fragmentation (Ferrer et al., 2001) . In addition, preliminary data show a lack of increased Bad phosphorylation in the hippocampal neurons of human AD patients (T. D. Stein and J. A. Johnson, unpublished observations).
A diagram proposing how these pathways could interact to confer protection is shown in Figure 7 .
The changes in gene expression in the APP Sw overexpressing mice may be induced by APP or its metabolites such as A␤. Expression levels of the APP Sw transgene were similar in the hippocampus and cerebellum (Fig. 5A) . However, gene expression changes were markedly different between these two tissues, suggesting that it may be a cleavage product of APP Sw and not the APP Sw transgene itself that drives these changes. In fact, cleavage of APP by ␣-secretase generates a secreted form of APP, which is neuroprotective in cultured hippocampal neurons (Mattson et al., 1993) . Furthermore, secreted APP has been shown to activate Erk1/2 in PC-12 cells in a Ras-dependent manner (Greenberg et al., 1994) , and phosphorylated Erk1/2, in turn, is important in growth factor-induced secretion of ␣-secretase-cleaved APP (Mills et al., 1997) . One difference between the APP Sw mouse model and AD is the fivefold to sixfold overexpression of APP Sw in the mouse (Hsiao et al., 1996) . Therefore, it may be the subsequent increase in the secreted form of APP that drives the protective gene expression changes described here.
Substantial evidence indicates a protective role for TTR, IGF-2, Akt, Erk, and Bad phosphorylation in vitro. Here we provide evidence that suggests these mechanisms are neuroprotective against A␤ in vivo. Thus, regulating the transcription of these genes and/or the identified signal transduction pathways may have an important role in the design of potential AD therapeutics. 
